Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38264

1.

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

Schmaltz CAS, Demitto FO, Sant'Anna FM, Rolla VC.

Mem Inst Oswaldo Cruz. 2019 Feb 11;114:e180420. doi: 10.1590/0074-02760180420.

2.

Risk Compensation and Clinical Decision Making - The Case of HIV Preexposure Prophylaxis.

Marcus JL, Katz KA, Krakower DS, Calabrese SK.

N Engl J Med. 2019 Feb 7;380(6):510-512. doi: 10.1056/NEJMp1810743. No abstract available.

3.

Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.

Cattaneo D, Capetti A, Rizzardini G.

Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):245-252. doi: 10.1080/17425255.2019.1577821. Epub 2019 Feb 11. Review.

PMID:
30704313
4.

Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity.

Wu H, Ma G, Yang Q, Zhu Y, Huang L, Tian Y, Yang X, Zhang M, Chen CH, Morris-Natschke SL, Yang M, Xu X, Lee KH.

Eur J Med Chem. 2019 Mar 15;166:159-166. doi: 10.1016/j.ejmech.2019.01.020. Epub 2019 Jan 10.

PMID:
30703659
5.

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.

Pham HT, Mesplède T.

Expert Opin Pharmacother. 2019 Mar;20(4):385-397. doi: 10.1080/14656566.2018.1560423. Epub 2019 Jan 30. Review.

PMID:
30698467
6.

HIV-Challenges for Human.

Geronikaki A.

Curr Top Med Chem. 2018;18(25):2136-2137. doi: 10.2174/156802661825190118123243.

PMID:
30698104
7.

Switching strategies in the recent era of antiretroviral therapy.

Prieto P, Podzamczer D.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):235-247. doi: 10.1080/17512433.2019.1575728. Epub 2019 Feb 13. Review.

PMID:
30691315
8.

Symfi, Symfi Lo, and Cimduo for HIV.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;61(1563):e8-e10. No abstract available.

PMID:
30681663
9.

A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation.

Violari A, Cotton MF, Kuhn L, Schramm DB, Paximadis M, Loubser S, Shalekoff S, Da Costa Dias B, Otwombe K, Liberty A, McIntyre J, Babiker A, Gibb D, Tiemessen CT.

Nat Commun. 2019 Jan 24;10(1):412. doi: 10.1038/s41467-019-08311-0.

10.

Juluca - a two-drug complete regimen for HIV.

[No authors listed]

Med Lett Drugs Ther. 2018 Dec 3;60(1561):e202-e204. No abstract available.

PMID:
30653480
11.

[HIV co-infection in patients followed up for tuberculosis in the Division of Infectious Diseases at the Ibn Rochd University Hospital in Casablanca].

Kettani AE, Jebbar S, Takourt B, Maaloum F, Diraa O, Farouqi B, Zerouali K, Filali KME.

Pan Afr Med J. 2018 Aug 16;30:276. doi: 10.11604/pamj.2018.30.276.13913. eCollection 2018. French.

12.

HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme.

Dharan NJ, Radovich T, Che S, Petoumenos K, Juneja P, Law M, Huang R, McManus H, Polizzotto MN, Guy R, Cronin P, Cooper DA, Gray RT.

BMC Public Health. 2019 Jan 3;19(1):13. doi: 10.1186/s12889-018-6325-5.

13.

An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.

Giacomet V, Cossu MV, Capetti AF, Zuccotti G, Rizzardini G.

Expert Opin Pharmacother. 2019 Feb;20(3):269-276. doi: 10.1080/14656566.2018.1559299. Epub 2018 Dec 26. Review.

PMID:
30586314
14.

Evaluation of non-adherence to anti-retroviral therapy, the associated factors and infant outcomes among HIV-positive pregnant women: a prospective cohort study in Lesotho.

Kadima N, Baldeh T, Thin K, Thabane L, Mbuagbaw L.

Pan Afr Med J. 2018 Jul 31;30:239. doi: 10.11604/pamj.2018.30.239.14532. eCollection 2018.

15.

Prevalence of HIV-1 transmitted drug resistance and viral suppression among recently diagnosed adults in São Paulo, Brazil.

Coelho LPO, Matsuda EM, Nogueira RS, de Moraes MJ, Jamal LF, Madruga JVR, Tancredi MV, de Leão ACQ, de Faria Romero Soldi G, de Macedo Brígido LF; MIHR workgroup.

Arch Virol. 2019 Mar;164(3):699-706. doi: 10.1007/s00705-018-04122-8. Epub 2018 Dec 20.

PMID:
30569276
16.

Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.

Liu P, Liao L, Xu W, Yan J, Zuo Z, Leng X, Wang J, Kan W, You Y, Xing H, Ruan Y, Shao Y.

Medicine (Baltimore). 2018 Dec;97(50):e13555. doi: 10.1097/MD.0000000000013555.

17.

Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines.

McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, Luban J.

Nat Commun. 2018 Dec 13;9(1):5305. doi: 10.1038/s41467-018-07753-2.

18.

Tendering for HIV drugs is not clinically justified.

Trøseid M, Nordøy I, Fevang B, Aukrust P.

Tidsskr Nor Laegeforen. 2018 Nov 30;138(20). doi: 10.4045/tidsskr.18.0808. Print 2018 Dec 11. Norwegian. No abstract available.

19.

Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions.

Miller Iii WA, Teye J, Achieng AO, Mogire RM, Akala H, Ong'echa JM, Rathi B, Durvasula R, Kempaiah P, Kwofie SK.

Curr Top Med Chem. 2019;18(23):2022-2028. doi: 10.2174/1568026619666181130133548. Review.

PMID:
30499404
20.

Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.

Liu W, Meng Q, Sun Y, Wang C, Huo X, Liu Z, Sun P, Sun H, Ma X, Liu K.

Cell Physiol Biochem. 2018;51(4):1616-1631. doi: 10.1159/000495650. Epub 2018 Nov 29.

Supplemental Content

Loading ...
Support Center